Article information
Full text is only aviable in PDF
REFERENCES
[1]
CM Fletcher.
Chronic bronchitis, its prevalence, nature and pathogenesis.
Am Rev Respir Dis., 80 (1959), pp. 483-494
[2]
CM Fletcher, R Peto, C Tinker, FE Speizer.
The natural history of chronic bronchitis and emphysema, Oxford University Press, (1976),
[3]
RA Pauwels, AS Buist, PM Calverley, CR Jenkins, SS Kurd.
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLB/WHO Global initiative for chronic obstructive lung disease (GOLD) workshop summary.
Am J Respir Crit Care Med, 163 (2001), pp. 1256-1276
[4]
BR Celli, W MacNee.
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper.
Eur Respir J, 23 (2004), pp. 932-946
[5]
JJ Soler, L Sanchez, MA Martinez, P Roman, E Salcedo, M Navarro.
Mid-arm muscle area is a better predictor of mortality than body mass index in COPD.
Chest, 128 (2005), pp. 2108-2115
[6]
AMWJ Schols, R Broekhuizen, CA Weling-Scheepers, EF Wouters.
Body composition and mortality in chronic obstructive pulmonary disease.
Am J Clin Nutr, 82 (2005), pp. 53-59
[7]
BWM Willemse, NHT ten Hacken, B Rutgers, IGAT Iesman-Leegte, DS Postma, W Timens.
Effect of 1 -year smoking cessation on airway inflammation in COPD and asymptomatic smokers.
Eur Respir J, 26 (2005), pp. 835-845
[8]
JC Hogg, F Chu, S Utokaparch, R Woods, WM Elliot, L Buzatu, et al.
The nature of small-airway obstruction in chronic obstructive pulmonary disease.
N Engl J Med, 350 (2004), pp. 2645-2653
[9]
DD Sin, SF Man.
Skeletal muscle weakness, reduced exercise tolerance, and COPD: is systemic inflammation the missing link?.
Thorax, 61 (2006), pp. 1-3
[10]
GC Donaldson, TAR Seemungal, IS Patel, A Bhowmik, TMA Wilkinson, JR Hurst, et al.
Airway and systemic inflammation and decline in lung function in patients with COPD.
Chest, 128 (2005), pp. 1995-2004
[11]
B Balbi, C Bason, E Balleari, F Fiasella, A Pesci, R Ohio, et al.
Increased bronchoalveolar granulocytes and granulocyte/macrophage colony stimulating factor during exacerbations of chronic bronchitis.
Eur Respir J, 10 (1997), pp. 846-850
[12]
M Tsoumakidou, N Tzanakis, G Chrysofakis, D Kyriakou, NM Siafakas.
Changes in sputum T-lymphocytes subpopulations at the onset of severe exacerbations of chronic obstructive pulmonary disease.
Respir Med, 99 (2005), pp. 572-579
[13]
A Bhowmik, TAR Seemungal, RJ Sapsford.
Relation of sputum inflammatory markers to symptoms and lung function changes in COPD.
Thorax, 55 (2000), pp. 114-120
[14]
M Roland, A Bhowmik, RJ Sapsford, TA Seemungal, DJ Jeffries, TD Warner, et al.
Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease.
Thorax, 56 (2001), pp. 30-35
[15]
S Gompertz, C O'Brien, DL Bayley, SL Hill, RA Stockley.
Changes in bronchial inflammation during acute exacerbations of chronic bronchitis.
Eur Respir J, 17 (2001), pp. 1112-1119
[16]
IS Patel, TAR Seemungal, M Wilks, SJ Iloyd-Owen, GC Donaldson, JA Wedzicha.
Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations.
Thorax, 57 (2002), pp. 759-764
[17]
GC Donaldson, TAR Seemungal, A Bhowmik, JA Wedzicha.
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease.
Thorax, 57 (2002), pp. 847-852
[18]
TA Wilkinson, IS Patel, M Wilks, GC Donaldson, JA1 Wedzicha.
Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 167 (2003), pp. 1090-1095
[19]
TMA Wilkinson, GC Donaldson, SL Johnston, PJM Openshay, JA Wedzicha.
Respiratory syncytial vims, airway inflammation, and FEV1 decline in patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 173 (2006), pp. 871-876
[20]
J Vestbo, P Iange.
Can GOLD stage 0 provide information of prognostic value in chronic obstructive pulmonary disease?.
Am J Respir Crit Care Med, 166 (2002), pp. 329-332
[21]
J Vestbo, E Prescott, P Iange, the Copenhagen City Heart Study Group.
Association of chronic mucus hypersecretion with FEV1 decline and COPD morbidity.
Am J Respir Crit Care Med, 153 (1996), pp. 1530-1535
[22]
A Noguera, O Malo, J Sauleda, X Busquets, C Miralles, AGN Agusti.
Inflamacion sistemica durante las agudizaciones de la enfermedad pulmonarobstruct!va cronica.
Arch Bronconeumol, 38 (2002), pp. 172-176
[23]
JR Hurst, W Perera, TM Wilkinson, GC Donaldson, JA Wedzicha.
Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 173 (2006), pp. 71-78
[24]
DD Sin, SF Man.
Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular disease? The potential role of systemic inflammation in chronic obstructive pulmonary disease.
Circulation, 107 (2003), pp. 1514-1519
[25]
SFP Man, JE Connet, NR Anthonisen, RA Wise, DP Tashkin, DD Sin.
C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease.
Thorax, 61 (2006), pp. 849-853
[26]
AF Connors, NV Dawson, C Thomas, FE Harrell, N Desbiens, WJ Fulkerson, et al.
Outcomes following acute exacerbation of severe chronic obstructive lung disease.
Am J Respir Crit Care Med, 154 (1996), pp. 959-967
[27]
P Almagro, E Calbo, A Ochoa de Echagiien, B Barreiro, S Quintana, JL Heredia, et al.
Mortality after hospitalization for COPD.
Chest, 121 (2002), pp. 1441-1448
[28]
KH Groenewegen, AMWJ Schols, E Wouters.
Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD.
Chest, 124 (2003), pp. 459-467
[29]
JJ Soler-Cataluna, MA Martinez-Garcia, P Roman Sanchez, E Salcedo, M Navarro, R Ochando.
Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease.
Thorax, 60 (2005), pp. 925-931
[30]
JV Iightowler, JA Wedzicha, MW Elliot, FS Ram.
Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis.
BMJ, 326 (2003), pp. 185-189
[31]
PK Plant, JL Owen, MW Elliot.
Non-invasive ventilation in acute exacerbations of chronic obstructive pulmonary disease: long term survival and predictors of in-hospital outcome.
Thorax, 56 (2001), pp. 708-712
[32]
A Alsaedi, DD Sin, FA McAlister.
The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomised placebo-controlled trials.
Am J Med, 113 (2002), pp. 59-65
[33]
DD Sin, L Wu, JA Anderson, NR Anthonisen, AS Buist, PS Surge, et al.
Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease.
Thorax, 60 (2005), pp. 992-997
[34]
P Calverley, R Pauwels, J Vestbo, P Jones, N Pride, A Gulsuik, et al.
Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial.
Lancet, 361 (2003), pp. 449-456
[35]
W Szafransky, A Cukier, A Ramirez, G Menga, R Sansores, S Nahabedian, et al.
Efficacy and safety of budesonide/formoterol and formoterol in chronic obstructive pulmonary diseases.
Eur Respir J, 22 (2003), pp. 912-918
[36]
T Ferguson, PMA Calverley, JA Anderson, B Celli, C Jenkins, PW Jones, et al.
The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years.
Eur Respir J, 28 (2006), pp. 34s
[37]
DE Niewoehner, K Rice, C Cote, et al.
Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial.
Ann Intern Med, 143 (2005), pp. 317-326
[38]
J Garcia-Aymerich, P Iange, M Benet, P Schnohr, JM Anto.
Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population-based cohort study.
Thorax, 61 (2006), pp. 772-778
[39]
AJ White, S Gompertz, DL Bayley, SL Hill, C O'Brien, I Unsal, et al.
Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis.
Thorax, 58 (2003), pp. 680-685
[40]
JJ Soler, MA Maitinez-Garcia, P Roman, R Orero, S Terrazas, A Martmez-Pechuan.
Eficacia de un programa especifico para pacientes con EPOC que presentan frecuentes agudizaciones.
Arch Bronconeumol, 42 (2006), pp. 501-508
Copyright © 2007. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
